A new predictive biomarker of immunotherapy benefit in triple-negative breast cancer was validated in the NeoTRIP trial
The 27-gene signature DetermaIO characterizing the tumor immune microenvironment was validated as predictive of immunotherapy benefit in the NeoTRIP trial from Fondazione Michelangelo